Keyphrases
Human Glioblastoma
100%
Androgen Receptor Antagonist
100%
Bicalutamide
100%
Temozolomide
75%
Enzalutamide
75%
Glioblastoma
50%
Monotherapy
50%
Glioma-initiating Cells
50%
U87MG
50%
Area under the Curve
25%
Dose Effect
25%
Mouse Model
25%
Nude Mice
25%
Cell Death
25%
Ineffective Treatment
25%
Long Lifespan
25%
Brain Tumor
25%
Fold Increase
25%
Patient Outcomes
25%
Combination Therapy
25%
Brain Tissue
25%
Dose-response Relationship
25%
Median Survival Time
25%
Androgen Receptor Expression
25%
Glioblastoma Xenografts
25%
Xtandi
25%
Neuroscience
Receptor Antagonist
100%
Androgen Receptor
100%
Bicalutamide
80%
Enzalutamide
80%
Temozolomide
60%
Cell Line
40%
Cell Death
20%
Receptor Expression
20%
Intracranial Tumor
20%
Pharmacology, Toxicology and Pharmaceutical Science
Glioblastoma
100%
Androgen Receptor Antagonist
100%
Enzalutamide
50%
Bicalutamide
50%
Temozolomide
37%
Monotherapy
25%
Disease
12%
Mouse Model
12%
Nude Mouse
12%
Combination Therapy
12%
Androgen Receptor
12%
Median Survival Time
12%
Intracranial Tumor
12%